JP2023106433A5 - - Google Patents

Download PDF

Info

Publication number
JP2023106433A5
JP2023106433A5 JP2023075458A JP2023075458A JP2023106433A5 JP 2023106433 A5 JP2023106433 A5 JP 2023106433A5 JP 2023075458 A JP2023075458 A JP 2023075458A JP 2023075458 A JP2023075458 A JP 2023075458A JP 2023106433 A5 JP2023106433 A5 JP 2023106433A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023075458A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023106433A (ja
Filing date
Publication date
Priority claimed from JP2020505208A external-priority patent/JP2020529410A/ja
Application filed filed Critical
Publication of JP2023106433A publication Critical patent/JP2023106433A/ja
Publication of JP2023106433A5 publication Critical patent/JP2023106433A5/ja
Priority to JP2025092507A priority Critical patent/JP2025131681A/ja
Pending legal-status Critical Current

Links

JP2023075458A 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質 Pending JP2023106433A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025092507A JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539421P 2017-07-31 2017-07-31
US62/539,421 2017-07-31
JP2020505208A JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020505208A Division JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025092507A Division JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Publications (2)

Publication Number Publication Date
JP2023106433A JP2023106433A (ja) 2023-08-01
JP2023106433A5 true JP2023106433A5 (enExample) 2023-12-01

Family

ID=65233032

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505208A Pending JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質
JP2023075458A Pending JP2023106433A (ja) 2017-07-31 2023-05-01 Nkg2d、cd16及びflt3と結合するタンパク質
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020505208A Pending JP2020529410A (ja) 2017-07-31 2018-07-31 Nkg2d、cd16及びflt3と結合するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025092507A Pending JP2025131681A (ja) 2017-07-31 2025-06-03 Nkg2d、cd16及びflt3と結合するタンパク質

Country Status (15)

Country Link
US (1) US20200165344A1 (enExample)
EP (1) EP3661554A4 (enExample)
JP (3) JP2020529410A (enExample)
KR (2) KR20250051800A (enExample)
CN (1) CN111132698A (enExample)
AU (2) AU2018309712A1 (enExample)
BR (1) BR112020001972A2 (enExample)
CA (1) CA3070986A1 (enExample)
CO (1) CO2020001981A2 (enExample)
EA (1) EA202090387A1 (enExample)
IL (1) IL272374A (enExample)
MA (1) MA49769A (enExample)
MX (1) MX2020001257A (enExample)
SG (1) SG11202000632QA (enExample)
WO (1) WO2019028027A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
JOP20200234A1 (ar) 2018-03-27 2020-09-15 Xyphos Biosciences Inc نطاقات a1-a2 معدلة لمركبات ترابطية nkg2d غير طبيعية ترتبط بمستقبلات nkg2d غير طبيعية.
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
AU2019404098A1 (en) 2018-12-18 2021-05-27 Boehringer Ingelheim Io Canada Inc. FLT3 agonist antibodies and uses thereof
AR120223A1 (es) * 2019-10-15 2022-02-02 Dragonfly Therapeutics Inc Proteínas que unen nkg2d, cd16 y flt3
IL295448A (en) * 2020-02-21 2022-10-01 Harpoon Therapeutics Inc flt3 binding proteins and methods of use
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
CN117580865A (zh) * 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
WO2026052582A1 (en) 2024-09-04 2026-03-12 Red Ridge Bio Ag Biparatopic antibodies that specifically bind fms related receptor tyrosine kinase 3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5591712B2 (ja) * 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー/エス ヒトnkg2dに対する抗体とその使用
AR071891A1 (es) * 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
JP5944831B2 (ja) * 2009-12-23 2016-07-05 シュニムネ ゲーエムベーハーSYNIMMUNE GmbH 抗flt3抗体及びその使用方法
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2794658B1 (en) * 2011-12-19 2017-03-15 Synimmune GmbH Bispecific antibody molecule
JP6628966B2 (ja) * 2012-06-14 2020-01-15 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
DK3126384T3 (da) * 2014-04-01 2021-01-18 Adimab Llc Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells

Similar Documents

Publication Publication Date Title
JP2023106433A5 (enExample)
JP2023052214A5 (enExample)
Hosseini et al. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials
JP2021098732A5 (enExample)
JP2020531438A5 (ja) Nkg2d、cd16、およびhla−eに結合するタンパク質
JP2020529410A5 (enExample)
JP2021098733A5 (enExample)
JP2020507328A5 (enExample)
JP2020510646A5 (enExample)
JP2020508997A5 (enExample)
JP2022061993A5 (enExample)
JP2020521448A5 (enExample)
JP2020507577A5 (enExample)
JP2020522474A5 (enExample)
JP2020533311A5 (ja) NKG2D、CD16およびNectin4に結合するタンパク質
JP2023123726A5 (enExample)
RU2021110369A (ru) Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген
JP2019536430A5 (enExample)
JPWO2020033702A5 (enExample)
JP2020522473A5 (enExample)
GB2597851A (en) Antibody molecules that bind to NKP30 and uses thereof
RU2019129511A (ru) Белки, связывающие gd2, nkg2d и cd16
JPWO2020033587A5 (enExample)
RU2019128204A (ru) Белки, связывающиеся с psma, nkg2d и cd16
JPWO2021076564A5 (enExample)